Clinical Oncology
Volume 16, Issue 8 , Pages 549-560 , December 2004

The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies

  • Graeme Morgan

      Affiliations

    • Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia
    • Corresponding Author InformationAuthor for correspondence: Dr Graeme W. Morgan, Director, Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney NSW 2065, Australia. Tel: +61-2-9926-5010; Fax: +61-2-9906-4150.
    • ,
  • Robyn Ward

      Affiliations

    • Department of Medical Oncology, St Vincent's Hospital, Sydney, NSW, Australia
    • ,
  • Michael Barton

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Health Service, Sydney, NSW, Australia

Received 18 August 2003 ,Revised 20 April 2004 ,Accepted 3 June 2004.

References 

  1. DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:889–895
  2. Lowenbraun S, DeVita VT, Serpick AA. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer. 1970;25:1018–1025
  3. Einhorn LH, Donohue JP. Improved chemotherapy in disseminated testicular cancer. J Urol. 1977;117:65–69
  4. Bonadonna G, Brusamolino E, Valagussa P, et al.  Combination chemotherapy as an adjunct treatment in operable breast cancer. N Engl J Med. 1976;294:405–410
  5. Braverman AS. Medical oncology in the 1990s. Lancet. 1991;337:901–902
  6. Kearsley JH. Cytotoxic chemotherapy for common adult malignancies: “the emperor's new clothes” revisited. BMJ. 1986;293:871–876
  7. Weissman DE, O'Donnell J, Brady A. A cry from the fringe. [letter] J Clin Oncol. 1993;11:1006
  8. Tannock IF. Conventional cancer therapy: promise broken or promise delayed?. Lancet. 1998;351(suppl II):9–16
  9. Slater S. Non-curative chemotherapy for cancer — is it worth it?. Clin Med. 2001;1:220–222
  10. Verweij J, de Jonge MJA. Achievements and future of chemotherapy. Eur J Cancer. 2000;36:1479–1487
  11. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomised studies comparing third generation regimens with CHOP. Br J Cancer. 2001;84:303–307
  12. The International Collaborative Ovarian Neoplasm (ICON) Group . Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–515
  13. Breathnach OS, Freidlin B, Conley B, et al.  Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734–1742
  14. Carney DN, Hansen HH. Non-small cell lung cancer — stalemate or progress. [editorial] N Engl J Med. 2000;343:1261–1263
  15. Early Breast Cancer Trialists' Collaborative Group . Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942
  16. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum. 1997;40:35–41
  17. Pignon JP. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949–955
  18. Crown J. A ‘bureausceptic’ view of cancer drug rationing. [commentary] Lancet. 2001;358:1660
  19. Cassidy J, Bridgewater J, Mainwaring P, Steward W, Wasan H. Is the NICE process flawed [letter]?. Lancet. 2002;359:2119–2120
  20. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002;325:269–271
  21. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR) . Cancer in Australia 1998: AIHW cat. no. CAN 12. Cancer series no. 17. Canberra: AIHW; 2001; http://www.aihw.gov.au/publications
  22. Cancer Statistics Branch NCI . SEER Cancer Incidence Public-use Database 1973–1998. Bethesda: National Cancer Institute; 2000;
  23. South Australian Cancer Registry . Epidemiology of cancer in South Australia. Incidence, mortality and survival 1997 to 1998. Incidence and mortality 1998. Analysed by type and geographical location. Twenty-two years of data. Adelaide: Openbook Publishers; 1999;
  24. Hill D, Jamrozik K, White V, et al.  Surgical management of breast cancer in Australia in 1995. Wooloomooloo (NSW): NHMRC National Breast Cancer Centre; 1999;
  25. Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990;61:759–762
  26. Munro AJ. An overview of randomised trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83–91
  27. El-Sayed S. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of head and neck region. A meta-analysis of prospective and randomised trials. J Clin Oncol. 1996;14:838–847
  28. Forastiere A, Goepfert H, Major M. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  29. Lin J-C, Jan J-S, Hsu C-Y, et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–637
  30. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer Survival in Australia 2001 Part I: National Summary Statistics (Cancer Series No 18). [http://www.aihw.gov.au/publications].
  31. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic oesophageal cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  32. Medical Research Council Oesophageal Cancer Working Party . Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised trial. Lancet. 2002;359:1727–1733
  33. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic eosophageal cancer (Cochrane Review). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd; 2003; Issue 4
  34. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the oesophagus (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  35. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, et al.  Adjuvant therapy after curative resection for gastric cancer: a meta-analysis of randomised trials. J Clin Oncol. 1993;11:1441–1447
  36. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059–1064
  37. Mari E, Floriani I, Buda A, et al.  Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: meta-analysis of published randomised trials. A study of GISCAD (Gruppo Italiano per Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837–843
  38. Macdonald JS, Smalley SR, Benedetti J, et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  39. Estes NC, Macdonald JS, Touijer K, et al.  Inadequate documentation and resection for gastric cancer in the United States. A preliminary report. Am Surg. 1998;64:680–685
  40. Wanebo H, Kennedy BJ, Chmiel J, et al.  Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–592
  41. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators . Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–944
  42. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT B2) Investigators . Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17:1356–1363
  43. Mamounas E, Wieand S, Wolmark N, et al.  Comparative efficacy of adjuvant chemotherapy in patients with Duke's B versus Duke's C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03 and C-04). J Clin Oncol. 1999;17:1349–1355
  44. Hoverman JR. The logic of evidence. [letter] J Clin Oncol. 2000;18:942
  45. Harrington DP. The tea leaves of small trials. [editorial] J Clin Oncol. 1999;17:1336
  46. Liver Infusion Meta-analysis Group . Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497–505
  47. Krook JE, Moertel CG, Mayer RJ, et al.  Effective surgical adjuvant therapy of high-risk rectal carcinoma. N Engl J Med. 1991;324:709–715
  48. Fisher B, Wolmark N, Rockette H, et al.  Postoperative adjuvant chemotherapy and radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst. 1988;80:21–29
  49. Wolmark N, Wieand HS, Hyams DM, et al.  Randomised trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of rectum: National Surgical Adjuvant Breast and Bowel Project R-02. J Natl Cancer Inst. 2000;92:388–396
  50. UKCCCR Anal Cancer Trial Working Party . Epidermoid anal cancer: results from the UKCCCR randomised trail of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet. 1996;348:1049–1054
  51. Bartelink H, Roelofsen F, Eschwege F, et al.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomised trial of the European Organisation for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–2049
  52. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–3275
  53. Lassen UJ, Osterlind K, Hansen M, et al.  Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years — an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13:1215–1220
  54. Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909
  55. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy for non-small lung cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  56. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable non-small lung cancer. A meta-analysis. Ann Intern Med. 1996;125:723–729
  57. Teirney JF. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised trials. Br J Cancer. 1995;72:469–475
  58. Sarcoma Meta-Analysis Collaboration . Adjuvant chemotherapy for localised soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–1654
  59. Sarcoma Meta-analysis Collaboration (SMAC) . Adjuvant chemotherapy for localised resectable soft tissue sarcomas in adults (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  60. International Breast Cancer Study Group (IBCSG) . Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomised trial. J Natl Cancer Inst. 2002;94:1054–1065
  61. Green JA, Kirwan JM, Tierney JF, et al.  Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–786
  62. Green J, Kirwan J, Tierney J, et al.  Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  63. Ovarian Cancer Meta-Analysis Project . Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian cancer: a meta-analysis. J Clin Oncol. 1991;9:1668–1674
  64. Advanced Ovarian Cancer Trialists Group . Chemotherapy in advanced ovarian cancer: an overview of randomised trials. BMJ. 1991;303:884–893
  65. Williams CJ, Stewart L, Parmar M, et al.  Meta-analysis of the role of platinum compounds in advanced ovarian cancer. Semin Oncol. 1992;19(suppl 2):120–128
  66. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1997;18:343–348
  67. Advanced Ovarian Trialists' Group . Chemotherapy in advanced ovarian cancer: four systematic meta-analysis of individual patient data from 37 randomised trials. Br J Cancer. 1998;78:1479–1487
  68. Advanced Ovarian Cancer Trialists' Group . Chemotherapy for advanced ovarian cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  69. The ICON Collaborators . ICON2: randomised trail of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet. 1998;352:1571–1576
  70. Tattersall MHN, Swanson CE, Solomon HJ. Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. Gynaecol Oncol. 1992;47:292–297
  71. Morgan GW, Leong T, Berg D. Management of seminoma of testis: recommendations based on treatment results. Aust NZ J Surg. 1997;67:15–20
  72. Advanced Bladder Cancer Overview Collaboration . Does neoadjuvant cis-platinum based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomised clinical trials. Br J Urol. 1995;75:206–213
  73. Advanced Bladder Cancer Overview Collaboration . Neoadjuvant cisplatin for advanced bladder cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  74. International Collaboration of Trialists . Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533–540
  75. Grossman HB, Natale RB, Tangen CM, et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866
  76. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration . Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–1934
  77. Fine HA. Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–2597
  78. Graham PH. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. [letter] Cancer. 1993;72:3367
  79. Huncharek M. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a met-analysis. Anticancer Res. 1998;18:4693–4697
  80. Glioma Meta-analysis Trialists (GMT) Group . Chemotherapy in adult high-grade glioma (Cochrane Review). The Cochrane Library. Oxford: Update Software Ltd; 2002; Issue 4
  81. Woods RL, Fox RM, Tattersall MHN, Levi J, Brodie GN. Metastatic carcinoma of unknown primary site: a randomised study of two combination-chemotherapy regimens. N Engl J Med. 1980;303:87–89
  82. Dowell JE, Garrett AM, Shyr Y, et al.  A randomised phase II trial in patients with carcinoma of an unknown primary site. Cancer. 2001;91:592–597
  83. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome in early-stage Hodgkin's disease: a meta-analysis of 23 randomised trials involving 3,888 patients. International Hodgkin's disease collaborative group. J Clin Oncol. 1998;16:830–843
  84. Loeffler M, Brosteanu O, Hasenclever D, et al.  Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International database on Hodgkin's disease overview study group. J Clin Oncol. 1998;16:818–829
  85. Myeloma Trialists' Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomised trials. J Clin Oncol. 1998;16:3832–3842
  86. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):
  87. Bagnall A-M, Forbes C, Lewis R, Golder S, Riemsma R, Kleijnen J. An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer. National Institute for Clinical Excellence Assessment Report 55. http://www.nice.org.UK/pdf/55_Paclitaxel_ovarianreview_Assessmentreport.pdf
  88. Lyngstadaas A. Primary treatment of ovarian cancer. Oslo: The Norwegian Centre for Health Assessment Technology (SMM); 2003;
  89. Choo C, Studts JL, Abell T, et al.  Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol. 2003;21:4299–4305
  90. Wieand HS. Is relative risk reduction a useful measure for patients or families who must choose a method of treatment [editorial]?. J Clin Oncol. 2003;21:4263–4264
  91. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?. J Natl Cancer Inst Monogr. 2001;30:146–152
  92. Silvestri G, Pritchard R, Welch G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771–775
  93. Editorial. Stem-cell transplantation for high-risk breast cancer. N Engl J Med. 2003;349:80–82
  94. Taratarone A, Romano G, Galasso R, et al.  Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. Bone Marrow Transplant. 2003;31:130–136
  95. Meinardi MT, van der Graaf WTA, van Veldhuisen DJ, Gietema JA, de Vries GE, Sleijfer D. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rep. 1999;25:237–247
  96. Tchen N, Juffs HG, Downie FP, et al.  Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175–4183
  97. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet. 1997;2:1174–1176
  98. Goodwin PJ. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer [editorial]?. J Clin Oncol. 2003;21:4474–4475
  99. Doyle C, Crump M, Pinitilie M, Oza AM. Does palliative care palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19:1266–1274
  100. Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens R. Do patients with advanced breast cancer benefit from chemotherapy?. Br J Cancer. 1998;78:1479–1487
  101. Cooper RG. Combination chemotherapy in hormone resistant breast cancer. [abstract] Proc Am Assoc Cancer Res. 1969;10:15
  102. Edelsteyn GA, Macrae ED. Cyclical combination chemotherapy in advanced carcinoma of breast. Br J Cancer. 1973;28:459–461
  103. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26:151–168
  104. Fossati R, Confalonieri C, Torri V, et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol. 1998;16:3439–3460
  105. Bernhard J, Cella DF, Coates AS, et al.  Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med. 1998;17:517–532
  106. Chvetzoff G, Tannock IF. Placebo effects in oncology. J Natl Cancer Inst. 2003;95:19–29
  107. Hrobjartsson A, Gotzsche PC. Is the placebo powerless?. N Engl J Med. 2001;344:1594–1602
  108. Therasse P. Measuring the clinical response. What does it mean?. Eur J Cancer. 2002;38:1817–1823
  109. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al.  Response rate accuracy in oncology trials: reasons for interobserver variability. J Clin Oncol. 1997;15:3507–3514
  110. Pharmaceutical Benefits Pricing Authority Annual Report for the year ending 30 June 2001. Table 6a Significant Drug Groups — 12 months to end June, sorted by highest Government cost 2000–2001: pp 36, 37. http://health.gov.au/pbs/pricing/pbparpt.htm.

PII: S0936-6555(04)00222-5

doi: 10.1016/j.clon.2004.06.007

Clinical Oncology
Volume 16, Issue 8 , Pages 549-560 , December 2004

Article Tools